ESSA Pharma Inc. (EPIX)

USD 1.61

(-1.83%)

Market Cap (In USD)

71.43 Million

Revenue (In USD)

-

Net Income (In USD)

-26.58 Million

Avg. Volume

56.73 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.4-11.67
PE
-
EPS
-
Beta Value
1.84
ISIN
CA29668H7085
CUSIP
29668H708
CIK
1633932
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. David Ross Parkinson M.D.
Employee Count
-
Website
https://www.essapharma.com
Ipo Date
2015-03-13
Details
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.